← Eichor
Study identifier: NCT05462496 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Condition: Pancreatic Cancer  ·  Sponsor: Icahn School of Medicine at Mount Sinai

PhasePhase 2
Planned participants25
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Deirdre Cohen, MD  ·  (212) 824-9331  ·  Deirdre.Cohen@mssm.edu

Rashmi Unawane  ·  rashmi.unawane@mssm.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Icahn School of Medicine at Mount SinaiNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05462496